Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 500 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tarceva, erlotinib, OSI-774 Clear all
Completed Phase 2 Interventional

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

NCT01316757
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
cetuximab, paclitaxel, carboplatin, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

NCT02155465
View directory record Official record
Conditions
Lung Cancer
Interventions
Ruxolitinib, Erlotinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

NCT00950365
View directory record Official record
Conditions
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
5
States / cities
Sacramento, California • Worcester, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01211483
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
U3-1287, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

NCT00365144
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting Phase 1 Interventional

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00045201
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Erlotinib Hydrochloride, Irinotecan Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cabozantinib S-malate, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
356
States / cities
Scottsdale, Arizona • Modesto, California • Monterey, California + 231 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Bevacizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

NCT01294306
View directory record Official record
Conditions
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma
Interventions
Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

NCT00063947
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
17
States / cities
Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

NCT02169284
View directory record Official record
Conditions
Bladder Carcinoma, Recurrent Bladder Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Baltimore, Maryland • Burlington, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated No phase listed Observational

TAURAS - T790 AURA ScreenFailure SOC Registry Study

NCT02405247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Patient Reported Outcome (PRO)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Oceanside, California • Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

NCT00087035
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, erlotinib hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Not applicable Interventional Results available

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

NCT02450591
View directory record Official record
Conditions
Oligometastatic Lung Adenocarcinoma
Interventions
Erlotinib, Local Therapies
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

NCT00043823
View directory record Official record
Conditions
Lung Cancer
Interventions
Avastin, Tarceva
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

NCT00393068
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Erlotinib, Bevacizumab, Paclitaxel, Carboplatin, 5-FU, Radiation therapy, Surgery
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Fort Myers, Florida • Jacksonville, Florida • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00617708
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
cixutumumab, erlotinib hydrochloride, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
146
States / cities
Jonesboro, Arkansas • Berkeley, California • Burlingame, California + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

NCT01900652
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Emibetuzumab, Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

NCT00304278
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
Drug · Radiation
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 14, 2026, 4:05 AM EDT
Terminated Phase 3 Interventional Results available

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

NCT02134015
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Patritumab, Erlotinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
20 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Glendale, Arizona • Duarte, California • La Verne, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 4:05 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

NCT02044601
View directory record Official record
Conditions
Lung Cancer
Interventions
Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 14, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

NCT00207077
View directory record Official record
Conditions
Neoplasms
Interventions
Cetuximab + Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 14, 2026, 4:05 AM EDT